NBRV - Nabriva Therapeutics AG - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

Nabriva Therapeutics AG's activity chart (see below) currently has 35 price targets and 21 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 92.16% with an average time for these price targets to be met of 933 days.

Most recent stock forecast was given by from NORTHLAND CAPITAL MARKETS on 06-Jan-2023. First documented stock forecast 13-Oct-2015.

Best performing analysts who are covering NBRV - Nabriva Therapeutics AG:

Adnan Butt Edward Nash Kevin Kedra David Lebowitz Robert Driscoll Louise Chen

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 30-Mar-2022

$1

$0.6 (150.00%)

$450

3 years 8 months 16 days ago
(06-Jan-2023)

1/3 (33.33%)

$-0.3 (-23.08%)

207

$50

$49.6 (12400.00%)

$7

5 years 9 months 15 days ago
(06-Dec-2020)

3/3 (100%)

$-44.5 (-47.09%)

837

Hold Since 19-Mar-2020

$6

$5.6 (1400.00%)

$7

6 years 6 months 3 days ago
(19-Mar-2020)

2/2 (100%)

$-136.5 (-95.79%)

886

Hold Since 02-May-2019

$2

6 years 8 months 13 days ago
(09-Jan-2020)

2/2 (100%)

$-535.5 (-99.63%)

1333

Buy Since 18-Sep-2017

$10

$9.6 (2400.00%)

7 years 4 months 21 days ago
(01-May-2019)

1/1 (100%)

$-532.5 (-98.16%)

1072

Show more analysts

Please expand the browser size to see the chart

What is NBRV (Nabriva Therapeutics AG) average time for price targets to be met?

On average it took 933 days for the stock forecasts to be reached, with an average price target met ratio of 92.16%.

Which analyst most recently updated their price target on NBRV (Nabriva Therapeutics AG)?

Which analyst has the most public recommendations on NBRV (Nabriva Therapeutics AG)?

has 0 price targets and 0 ratings on NBRV

Which analyst is the currently most bullish on NBRV (Nabriva Therapeutics AG)?

Adnan Butt with the highest potential upside of $5499.6

Which analyst is the currently most reserved on NBRV (Nabriva Therapeutics AG)?

Kevin Kedra with the lowest potential downside of -$0

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?